Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 105, pseudogene (RNU6-105P)
- Target
- RNU6-105P
- Molecular classification
- Pseudogene, Non-coding RNA, Small nuclear RNA (snRNA) variant (derived)
01
Overview
RNU6-105P is a human pseudogene related to the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a uridine-rich, non-coding RNA essential for nuclear intron splicing and is heavily modified and regulated within the cell nucleus[1][3]. Pseudogenes like RNU6-105P do not encode functional proteins; they arise from gene duplication, retrotransposition, or other evolutionary mechanisms and are typically transcriptionally silent or expressed at low levels[5]. While some pseudogenes can have regulatory RNA functions, such as acting as microRNA sponges or influencing gene expression[6], there is no evidence of RNU6-105P acting in these capacities. It is not a confirmed drug target or biomarker, and currently has minimal relevance for therapeutic intervention or disease association.
- Other names
- RNU6-105PRNA, U6 small nuclear RNA 105 pseudogene
02
Mechanism of action
None known. No therapeutics act on this pseudogene.
03
Biological functions
No experimentally confirmed function as a protein or direct biological activity. Pseudogenes like RNU6-105P may have subtle regulatory RNA roles, including antisense, competing endogenous RNA (ceRNA), or siRNA activity, but these functions are not experimentally established for RNU6-105P specifically.Related U6 snRNA parent is critical in pre-mRNA splicing, but the pseudogene itself is usually nonfunctional.
04
Disease associations
Most pseudogenes lack confirmed direct disease roles. Some pseudogenes can impact disease through RNA-mediated regulatory mechanisms, but no direct association for RNU6-105P is documented.Not established in cancer, inflammation, neurodegeneration, or other common disease categories.
05
Safety considerations
None applicable. As a non-coding pseudogene, it is not a direct therapeutic target and poses no safety concerns in drug development.
06
Interacting drugs
None known. No drugs are reported to target or interact with RNU6-105P.
07
Biomarkers
None reported for patient selection or efficacy monitoring.
Beyond the preview
Go deeper on RNA, U6 small nuclear 105, pseudogene (RNU6-105P).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA, U6 small nuclear 105, pseudogene (RNU6-105P).